Bio-Ved Pharmaceuticals Pvt. Ltd. has announced the launch of Artrex cream in the United States and Asia-Pacific markets. Artrex has been recently granted approval by the US FDA under the external analgesic OTC monograph.
Chairperson and CEO, Dr Deepa Chitre, Bio- Ved informed Pharmabiz that Artrex cream has eight different oils with well known anti-inflammatory properties, acting at various stages of inflammation and modulated to achieve maximum efficacy without any side effects.
"It permeates the outer layers of the skin to penetrate to the deeper tissues alleviating inflammation and consequent pain. It is formulated in a soothing, non-staining elegant cream base for easier and more appealing application," she added.
The cream provides fast and long lasting relief for the pains of rheumatic pain, arthritis, fibrositis, lumbago, sciatica, all types of musculo-skeletal pain, sprains, stiffness and sport injuries. She further informed the cream has been developed using the centuries of experience and knowledge from the science of ayurveda, and subsequently prepared, standardized and validated by modern methods.
Artrex cream is a valuable partner in conjunction with the US patented Artrex capsules. Dr. Chitre noted, "To the best of our knowledge, Artrex cream is the first ever product developed from Ayurvedic science to receive a US FDA approval. It has undergone extensive safety testing and clinical studies in osteo-arthritis and non-specific musculo-skeletal pain."
The company is launching the cream in the US and Asia-Pacific markets through its marketing partners in Japan, Singapore, Korea, Hong Kong and others. Dr. Chitre added, "Plans for introduction of the cream in the Indian market are underway. The company will be introducing four new products this year."